Podcast

What You Need to Know About Genomics

Author(s):

Kristie L. Kahl

In this week’s episode, we spoke with a patient and his doctor about genomic testing and how it can change treatment outcomes for patients with cancer.

Cancer is no longer the once thought “one-size-fits-all” approach when it comes to treatment, especially because genomic testing plays such a crucial role for certain patients.

This week, we spoke with Bryce, who was diagnosed with prostate cancer in 2014 and whose cancer journey was changed once he discovered what genomic testing could do for his treatment options. In addition, Dr. Marcia Brose, from the University of Pennsylvania, weighs in on what patients should know about genomic cancer testing.

To learn more, visit testyourcancer.com.

Related Videos
Image of man with black hair.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of man with brown and grey hair.
Dr. Kelly Stratton
Reginald Tucker-Seeley, MA, ScM, ScD, an expert on prostate cancer
Related Content
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
February 16th 2025

EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer

Roman Fabbricatore
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
"Prostate cancer" text.
February 14th 2025

Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer

Alex Biese
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months. | © pikovit - stock.adobe.com
February 13th 2025

Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT

Alex Biese
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.
Illustration of body highlighting prostate area.
February 13th 2025

Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer

Ryan Scott
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.